<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665273</url>
  </required_header>
  <id_info>
    <org_study_id>2015-4754</org_study_id>
    <nct_id>NCT02665273</nct_id>
  </id_info>
  <brief_title>Greater Occipital Nerve Block With Bupivacaine for Acute Migraine</brief_title>
  <official_title>A Randomized, Sham-controlled Trial of Greater Occipital Nerve Block as Second Line Therapy for ED Patients With Acute Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using&#xD;
      bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only&#xD;
      enrolled if they fail first line therapy with metoclopramide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are testing the following hypothesis:&#xD;
&#xD;
      In a population of patients who present to an ED with acute migraine and have been treated&#xD;
      with parenteral metoclopramide unsuccessfully, bilateral greater occipital nerve blocks with&#xD;
      bupivicaine will provide greater rates of short-term and sustained headache freedom than&#xD;
      bupivacaine injected intradermally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2015</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Achieve Freedom From Headache</measure>
    <time_frame>30 minutes</time_frame>
    <description>Pain assessed using a standard ordinal headache intensity scale, in which subjects describe their headache as &quot;severe&quot;, &quot;moderate&quot;, &quot;mild&quot;, or &quot;none&quot;. Those with headache level = none, experience freedom from headache.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Headache Relief</measure>
    <time_frame>48 hours</time_frame>
    <description>Attaining a headache level of &quot;mild&quot; or &quot;none&quot; within one hour of procedure and maintaining this for 48 hours without use of additional medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Would Want the Same Treatment Again During a Subsequent Migraine</measure>
    <time_frame>48 hours</time_frame>
    <description>Participants will be asked the following question: Do you want to receive the same procedure the next time you come to the ER with migraine?</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Pain Score Assessed by Verbal Pain Scale (0-10)</measure>
    <time_frame>60 minutes</time_frame>
    <description>The numerical scale, 0-10 pain scores will be obtained with 0 being &quot;no pain&quot; and 10 being &quot;the worst pain imaginable.&quot;</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Greater occipital nerve block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Greater occipital nerve block</intervention_name>
    <description>Bilateral greater occipital nerve block</description>
    <arm_group_label>Greater occipital nerve block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>0.5 cc of 0.5% bupivacaine injected intradermally</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ED patient with acute migraine or probable migraine&#xD;
&#xD;
          -  Fail first line therapy with metoclopramide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Can't obtain consent&#xD;
&#xD;
          -  Concern for secondary headache&#xD;
&#xD;
          -  Skull defect&#xD;
&#xD;
          -  Propensity for bleeding&#xD;
&#xD;
          -  Overlying infection&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Allergy, intolerance study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin W Friedman, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <results_first_submitted>November 7, 2019</results_first_submitted>
  <results_first_submitted_qc>July 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2020</results_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02665273/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Greater Occipital Nerve Block</title>
          <description>Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique&#xD;
Greater occipital nerve block: Bilateral greater occipital nerve block</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve&#xD;
Bupivacaine: 0.5 cc of 0.5% bupivacaine injected intradermally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Greater Occipital Nerve Block</title>
          <description>Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique&#xD;
Greater occipital nerve block: Bilateral greater occipital nerve block</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve&#xD;
Bupivacaine: 0.5 cc of 0.5% bupivacaine injected intradermally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="10"/>
                    <measurement group_id="B2" value="40" spread="12"/>
                    <measurement group_id="B3" value="38" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of headache</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96" lower_limit="60" upper_limit="160"/>
                    <measurement group_id="B2" value="48" lower_limit="24" upper_limit="100"/>
                    <measurement group_id="B3" value="72" lower_limit="24" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieve Freedom From Headache</title>
        <description>Pain assessed using a standard ordinal headache intensity scale, in which subjects describe their headache as &quot;severe&quot;, &quot;moderate&quot;, &quot;mild&quot;, or &quot;none&quot;. Those with headache level = none, experience freedom from headache.</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Greater Occipital Nerve Block</title>
            <description>Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique&#xD;
Greater occipital nerve block: Bilateral greater occipital nerve block</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve&#xD;
Bupivacaine: 0.5 cc of 0.5% bupivacaine injected intradermally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieve Freedom From Headache</title>
          <description>Pain assessed using a standard ordinal headache intensity scale, in which subjects describe their headache as &quot;severe&quot;, &quot;moderate&quot;, &quot;mild&quot;, or &quot;none&quot;. Those with headache level = none, experience freedom from headache.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Headache Relief</title>
        <description>Attaining a headache level of &quot;mild&quot; or &quot;none&quot; within one hour of procedure and maintaining this for 48 hours without use of additional medication</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Greater Occipital Nerve Block</title>
            <description>Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique&#xD;
Greater occipital nerve block: Bilateral greater occipital nerve block</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve&#xD;
Bupivacaine: 0.5 cc of 0.5% bupivacaine injected intradermally</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Headache Relief</title>
          <description>Attaining a headache level of &quot;mild&quot; or &quot;none&quot; within one hour of procedure and maintaining this for 48 hours without use of additional medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Would Want the Same Treatment Again During a Subsequent Migraine</title>
        <description>Participants will be asked the following question: Do you want to receive the same procedure the next time you come to the ER with migraine?</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Greater Occipital Nerve Block</title>
            <description>Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique&#xD;
Greater occipital nerve block: Bilateral greater occipital nerve block</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve&#xD;
Bupivacaine: 0.5 cc of 0.5% bupivacaine injected intradermally</description>
          </group>
        </group_list>
        <measure>
          <title>Would Want the Same Treatment Again During a Subsequent Migraine</title>
          <description>Participants will be asked the following question: Do you want to receive the same procedure the next time you come to the ER with migraine?</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Pain Score Assessed by Verbal Pain Scale (0-10)</title>
        <description>The numerical scale, 0-10 pain scores will be obtained with 0 being &quot;no pain&quot; and 10 being &quot;the worst pain imaginable.&quot;</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Greater Occipital Nerve Block</title>
            <description>Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique&#xD;
Greater occipital nerve block: Bilateral greater occipital nerve block</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve&#xD;
Bupivacaine: 0.5 cc of 0.5% bupivacaine injected intradermally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Score Assessed by Verbal Pain Scale (0-10)</title>
          <description>The numerical scale, 0-10 pain scores will be obtained with 0 being &quot;no pain&quot; and 10 being &quot;the worst pain imaginable.&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.8"/>
                    <measurement group_id="O2" value="5.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Greater Occipital Nerve Block</title>
          <description>Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique&#xD;
Greater occipital nerve block: Bilateral greater occipital nerve block</description>
        </group>
        <group group_id="E2">
          <title>Sham</title>
          <description>Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve&#xD;
Bupivacaine: 0.5 cc of 0.5% bupivacaine injected intradermally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin W. Friedman</name_or_title>
      <organization>Montefiore</organization>
      <phone>718-920-6626</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

